Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25

Benzinga Newsdesk www.benzinga.com Positive 73.3%

Neg 0% Neu 0% Pos 73.3%

Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.